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Abstract—The possibility of reopening an occluded cerebral artery by means of thrombolysis has renewed interest in a
number of the several mechanisms that are active during acute cerebral ischemia. Over recent years, it has become
apparent that leukocytes play a central role not only during the healing stage of brain infarction but also during the early
phases of cerebral ischemia, when it is postulated that these cells produce harmful effects, particularly in the presence
of reperfusion. This review is based on the critical analysis of more than 150 publications dealing with the role of
leukocytes and some inflammatory mediators (cytokines, chemokines, and adhesion molecules) in cerebral ischemia.
Animal studies indicate that leukocyte involvement is promoted by a variety of inflammatory molecules produced
immediately after the onset of cerebral ischemia. Considerable experimental evidence suggests that these mediators play
a key role in the progression from ischemia to irreversible injury (ie, cellular death and necrosis). However, the precise
role of each molecule alone remains to be further elucidated as well as in relation to the complex network existing among
different mediators. Progress in our understanding of the inflammatory mechanisms operating in cerebral ischemia has
enabled the testing of new compounds with promising results in animals; in contrast, one recent controlled trial of an
anti-leukocyte molecule in acute stroke patients showed negative results. This discrepancy may derive in part from our
incomplete understanding of the complexity of the inflammatory mechanisms involved in cerebral ischemia. Our
analysis suggests that until sufficient knowledge of the underlying disease mechanisms is acquired, more care should
be taken when testing new and potentially efficacious drugs in stroke patients.
The scenario of acute ischemic stroke therapy is rapidlyevolving, and thrombolysis has recently been approved
for use in stroke patients by USA authorities. However,
therapeutic recanalization of an occluded cerebral artery still
appears to be a potentially risky option that can be applied
only in the case of selected patients.1,2 The main limitation of
cerebral thrombolysis is the narrow, 3-hour therapeutic “win-
dow” during which the thrombolytic agent has to be admin-
istered to be effective3; beyond this time limit, its effective-
ness is neutralized by the high risk of cerebral hemorrhage.4
The rationale for the use of a number of other pharmaco-
logical treatments for acute stroke currently under study in
both animals and humans is based on recent advances in the
pathophysiology of brain ischemia, one of the most rapidly
expanding and promising areas of which is the role of
inflammation in stroke. This role involves (1) the molecules
that form part of the inflammatory response and participate in
the pathophysiological cascade after an ischemic insult and
(2) the inflammatory or infectious processes that may predis-
pose or precipitate atherothrombotic stroke.5–8 In this review,
we reexamine some aspects of inflammation in acute stroke
by focusing on the role of leukocytes and leukocyte-related
molecules, with the aim of providing the background neces-
sary to understand the rationale of newly emerging therapeu-
tic approaches. Our review is limited to experimental and
human data concerning some of the inflammatory mecha-
nisms active during the acute phase of cerebral ischemia.
Histological Inflammatory Aspects in Acute
Cerebral Ischemia
An inflammatory reaction is a common response of the brain
parenchyma to various forms of insult. It is histologically
characterized by the infiltration of leukocytes, which in the
case of cerebral ischemia are mainly polymorphonuclear
leukocytes and monocytes/macrophages.9 Human data are
scarce: an increased number of leukocytes has been docu-
mented in the cerebrospinal fluid of acute stroke patients 2 to
3 days after stroke10; a high number of radiolabeled poly-
morphonuclear leukocytes have been shown in slightly per-
fused brain areas as early as 6 to 12 hours after the ictus11; and
one autopsy study described intense leukocyte infiltration of
the brain parenchyma 2 to 3 days after the stroke.12
However, the inflammatory response of ischemic brain
parenchyma has been more thoroughly explored in animal
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models. An increased number of polymorphonuclear leuko-
cytes in the microvessels or ischemic brain parenchyma have
been found in various species.13–21 Until recently, it was
assumed that this inflammatory reaction was delayed, sec-
ondary to tissue necrosis, and was intended to remove tissue
debris from the infarcted area. In rats with permanent occlu-
sion of one MCA, leukocytes (particularly polymorphonu-
clear cells) can be recognized in the microvessels as early as
30 minutes after occlusion.22 In the same model, necrosis is
detected only 72 to 96 hours after MCA occlusion.23,24 This
study and others suggest that at least the early arrival of
leukocytes in the brain parenchyma is independent of the
presence of necrosis, and this idea leads to the hypothesis that
these cells play a role in the progression from ischemia to
brain infarction.
There are a number of mechanisms by which leukocytes
may produce deleterious effects on ischemic parenchyma. It
has been proposed that leukocytes obstruct the microvessels
and contribute toward the so-called “no-reflow” phenome-
non16: ie, the lack of complete recovery of cerebral blood flow
in the ischemic area after reperfusion.25 This plugging of
microvessels under ischemic conditions may be the result of
an interaction with endothelial cells, mediated by adhesion
molecules and/or the loss of cell deformability due to actin
polymerization and pseudopod projections.26,27 As reviewed
by Ha¨rtl et al,28 other detrimental effects of leukocytes during
ischemia may be due to: (1) the release of vasoconstrictive
mediators, such as superoxidase anions, thromboxane A2,
endothelin-1, and prostaglandin H2 29; (2) an alteration in
cerebral artery vasoreactivity; and (3) the release of cytotoxic
enzymes, free oxygen radicals, NO, and products of the
phospholipid cascade. The release of proteolytic enzymes
such as elastase might damage endothelial cell membranes
and the basal lamina, alter the blood-brain barrier, and
contribute to the formation of postischemic edema. In addi-
tion, loss of the integrity of the endothelial cell–basal lamina
lining might facilitate the escape of red blood cells and the
hemorrhagic transformation of a brain infarct.30,31
The view that leukocytes may cause additional damage to
potentially still-viable tissue during acute cerebral ischemia is
indirectly supported by data showing a smaller infarct volume
in neutropenic animals than in normal controls.32–35 Further-
more, a significant correlation has been found in humans
between the degree of leukocyte accumulation and infarct
volume as assessed by CT.11 The arrival of leukocytes in the
ischemic area is a multistep process.36 They first marginate in
the venules, then adhere to endothelial cells, and finally
migrate into the brain parenchyma. During each of these three
steps, their functions are regulated by the inflammation-
related molecules that are produced soon after the onset of
cerebral ischemia.
Cytokines and Cerebral Ischemia
The signals mediating the entry of leukocytes into the
ischemic area have not yet been completely elucidated, but a
number of clues suggest that cytokines play a key role in this
process. Cytokines are low-molecular-weight glycoproteins
that act as intercellular messengers and are produced by
macrophages, monocytes, lymphocytes, endothelial cells, fi-
broblasts, platelets, and many other cell types. To produce
cytokines, all of these cells need to be activated.37 Cytokines
act at very low concentrations on specific target-cell recep-
tors, whose expression is modulated by the cytokines them-
selves. Binding of cytokines to receptors activates intracellu-
lar second-messenger systems (yet to be identified) and
subsequently, protein kinases and phosphatases. These pro-
teins cause gene regulation through the activity of transcrip-
tion factors.37 Cytokines are considered to be among the
principal mediators of immunologic and inflammatory re-
sponses. In vitro, cytokines can be produced by astrocytes,
neurons, and endothelial and microglia cells,38–40 and there
are observations suggesting that this also holds true in
humans affected by brain ischemia.41
Cytokines may have various functions during cerebral
ischemia: on the one hand, they can attract leukocytes and
stimulate the synthesis of adhesion molecules in leukocytes,
endothelial cells, and other cells, thus promoting the inflam-
matory response of damaged cerebral tissue; on the other,
they can facilitate thrombogenesis by increasing the levels of
plasminogen-activating inhibitor-1, tissue factor, and plate-
let-activating factor42,43 and by inhibiting tissue plasminogen
activator and protein S.44 Examination of this last aspect is
beyond the scope of the present review.
IL-1
IL-1 exists in two separate forms (a and b), which have only
one-third sequence homology. IL-1 is overexpressed during
brain ischemia, as documented by the induction of IL-1b
mRNA synthesis in rats with permanent MCA occlusion,45,46
transient global forebrain ischemia,47–50 or a ligated carotid
artery associated with hypoxia.51 Attempts to detect IL-1 in
the peripheral blood of stroke patients have so far been
unsuccessful, conceivably because of its low plasma levels.52
Evidence that IL-1 may play a deleterious role in cerebral
ischemia derives from the observation that rats with a
transient MCA occlusion have a larger brain infarction when
recombinant human IL-1b is injected into the lateral ventricle
immediately after reperfusion.53 Similar results have been
obtained in rats with a permanent MCA occlusion.54 The
intraventricular injection of recombinant human IL-1b also
enhances the formation of brain edema and increases both the
number of neutrophils in ischemic areas and neutrophil–en-
dothelial cell adhesion.53 The complex functions of IL-1 are
mediated by specific cell-surface receptors and regulated by
the IL-1 receptor antagonist.55 Two main receptors for IL-1
have been identified; type I is present in many cell types and
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binds IL-1a and IL-1b with similar affinity.56 Type II is found
on the surface of B cells, neutrophils, and macrophages and
shows higher affinity for IL-1b.56 Types I and II are regulated
differently in brain ischemia and may thus play separate roles.
In spontaneously hypertensive rats, the mRNA for the type I
IL-1 receptor is relatively highly expressed in the normal
cortex, with a marked increase 5 days after cerebral ische-
mia.55 Type II mRNA has low basal expression and a peak 12
hours after the onset of ischemia.55 The possible mechanisms
of intracellular signal transduction for IL-1 on peripheral
immune cells include effects on cAMP, protein kinase C, and
protein phosphorylation56; these effects remain to be proved
in brain ischemia. The IL-1–receptor interaction is quickly
followed by the induction of immediate-early genes such as
c-jun and c-fos.57
Studies showing a reduction in infarct size after the
administration of IL-1 antagonists or inhibitors provide fur-
ther evidence of the importance of IL-1 in cerebral ische-
mia.53,58–64 The possible harmful mechanisms induced or
activated by IL-1 include fever, increased heart rate and
arterial blood pressure, enhancement of N-methyl-D-aspar-
tate–mediated injury, proliferation of microglia, release of
arachidonic acid, and stimulation of NO synthesis.65 At
present, the most widely recognized functions of IL-1 appear
to be the induction of endothelial cell adhesion molecule
expression and the promotion of neutrophil tissue infiltration.
TNF-a
TNF-a gene upregulation has been demonstrated in tran-
sient66 and prolonged51,67 cerebral ischemia by the increased
synthesis of TNF-a mRNA in the parenchyma. TNF-a
plasma levels have also been found to be higher in acute
stroke patients than in healthy control subjects.68
The effects of TNF-a are mediated by specific receptors,
the most well known of which are two proteins called p75 and
p55 (according to their molecular weight).69 The binding of
TNF-a to its receptor is followed by the activation of a
variety of proteins, such as protein kinase C, tyrosine kinase,
mitogen-activated protein kinase, phospholipase A2, and
phosphatidylcholine-specific phospholipase C.70 Among
these, the mitogen-activated protein kinases are the most
extensively studied, and they are divided into three main
families: (1) the extracellular signal–regulated kinases, which
are activated by growth factors; (2) the c-Jun NH2-terminal
kinases; and (3) the p38 kinases. The last two groups are
activated by proinflammatory cytokines.71,72 The second step
in the TNF-a signal transduction pathway, as for other
cytokines, is intranuclear, with the activation of several
transcription factors. One of these, nuclear factor-kB, trans-
locates from the cytoplasm to the nucleus, where it activates
the promoter of the genes for adhesion molecules and other
cytokines.73
Like IL-1, TNF-a induces the expression of adhesion
molecules by glial and endothelial cells,74 thus favoring
neutrophil adherence and accumulation in microvessels.67
TNF-a is also involved in blood-brain barrier alterations, a
proadhesive-procoagulant transformation of endothelial cell
surfaces, and glial cell activation.74 However, its role in
cerebral ischemia remains to be established. Barone et al75
showed that administration of TNF-a exacerbated the ische-
mic injury provoked by MCA occlusion in spontaneously
hypertensive rats, although TNF-a toxicity was not related to
direct neuronal damage, and also demonstrated that anti–
TNF-a antibodies have a neuroprotective effect.75 Similarly,
the inhibition of TNF-a in mice with permanent MCA
occlusion leads to a smaller infarct volume.76 However, not
all studies agree about the deleterious role of TNF-a in brain
ischemia. When TNF-a is administered to mice 48 hours
before MCA occlusion, it induces a protective effect.77
Furthermore, the fact that mice lacking TNF-a receptors
show a larger infarct area after MCA occlusion than do
normal controls78 suggests that TNF-a may be beneficial in
the poststroke recovery phase. Finally, the specificity of
TNF-a expression after cerebral ischemia has been chal-
lenged by preliminary human data showing that TNF-a is
also expressed in the contralateral, nonischemic hemisphere.79
IL-6
IL-6 plays a central role in host defense as well as in acute
and chronic inflammatory activities80,81 and is expressed in
response to various forms of brain injury.81–85 In the rat, IL-6
mRNA is overexpressed 3 hours after permanent MCA
occlusion and reaches a peak at 12 hours; its expression
remains high for at least 24 hours.86
Higher IL-6 levels have been detected in the peripheral
blood of patients with acute cerebral ischemia than in control
subjects.52,87–89 Increased plasma and cerebrospinal fluid IL-6
levels are correlated with a larger infarct size on CT and
magnetic resonance imaging scans87,88 and with a poorer
clinical outcome,52 although it is not clear whether this simply
reflects an overproduction of IL-6 by larger lesions or a
directly damaging effect of IL-6 itself. In addition, it has not
yet been completely elucidated whether IL-6 exerts anti-
inflammatory or proinflammatory effects or both. Its anti-
inflammatory effect depends on the inhibition of IL-1 and
TNF-a production via a negative-feedback mechanism and
stimulation of the production of their circulating antagonists:
soluble TNF-a receptor and IL-1 receptor antagonist.80,90 Part
of the anti-inflammatory function of IL-6 can be attributed to
its ability to induce the release of corticotropin and corti-
sol91,92 and to promote the expression of acute-phase pro-
teins93,94 that have antiproteinase and oxygen-scavenger func-
tions.81 On the other hand, it has also been shown that IL-6
induces phospholipase A2 gene expression and as a conse-
quence, stimulates the production of leukotrienes, prostaglan-
dins, and platelet activating factor,95 all of which are involved
in ischemic brain damage.96
TGF-b
TGF-b is a cytokine that is known to regulate and stimulate
cell proliferation and differentiation and to play a central role
in tissue repair mechanisms.97 In rats exposed to 10 minutes
of global cerebral ischemia, increased expression of TGF-b
mRNA is seen after 6 hours throughout the brain; this
expression increases further at day 2 and subsides thereafter.98
One recent human autopsy study has found TGF-b mRNA
overexpression in ischemic tissue in comparison with sam-
ples taken from the contralateral, nonischemic side.99 The
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highest expression of TGF-b mRNA was detected in the
tissue surrounding the infarction (the penumbra zone).99 A
so-far-unexplained finding is that serum TGF-b levels are
lower in acute stroke patients than in control subjects, perhaps
owing to an accumulation of this cytokine in the ischemic
tissue.89
Preliminary results indicate that TGF-b may play a pro-
tective role in brain ischemia.100–104 Some of the proposed
reasons for this beneficial effect include (1) reduced neutro-
phil adherence to endothelial cells105; (2) suppression of the
release of potentially harmful oxygen- and nitrogen-derived
products by macrophages106,107; (3) the promotion of angio-
genesis in the penumbra area99; and (4) a reduction in the
expression and efficacy of other cytokines, such as TNF-
a,108,109 possibly by blocking p38 kinase and the consequent
inhibition of the TNF-a transduction mechanism.110
IFN-g
IFN-g is a protein produced by activated CD41 and CD81 T
cells and, to a lesser degree, by natural killer cells.111 IFN-g is not
produced by central nervous system cells, and its release at this
level is possible only when a breakdown of the blood-brain
barrier allows infiltration of lymphocytes into the brain paren-
chyma. Although the role of IFN-g (and of all the IFNs) in brain
ischemia has not been specifically addressed, blood-brain barrier
damage and leukocyte penetration are among the first conse-
quences of ischemic cerebral insults. Among many different
functions, IFN-g induces the expression of a variety of cytokines
by stimulating p38 kinase110 and of class II major histocompat-
ibility complex. Major histocompatibility complex is essential
for macrophages to recognize antigen, and thus, IFN-g could
play a crucial role in the development of brain necrosis after an
ischemic insult. Another possible role of IFN-g in cerebral
ischemia is the production of NO, with a consequent cytotoxic
effect on brain cells; in vitro, IFN-g stimulates the production of
interferon regulatory factor-1, which induces NO synthase
mRNA expression.112
Cell Adhesion Molecules in Cerebral Ischemia
Cell-Cell Adhesion
The adhesion of leukocytes to the endothelial surface and
their subsequent migration from the microvessels into the
brain parenchyma is mediated by a variety of molecules
located on the surface of both leukocytes and endothelial
cells. Adhesion molecules are conventionally divided into
four main families, each of which has a different function:
integrins, the immunoglobulin superfamily, cadherins, and
selectins.113 Under normal conditions, there is little or no
cell-surface expression of adhesion molecules114; their expres-
sion is induced by various inflammatory processes, such as
cerebral ischemia, with the upregulation mediated by cyto-
kines. Among the most studied adhesion molecules are
ICAM-1 (immunoglobulin superfamily), which is located on
the endothelial surface, and its leukocyte counterpart, integrin
CD11/CD18; many others are currently under investigation.
A number of animal studies have documented the upregula-
tion of endothelial-leukocyte adhesion molecule 1 (also
called E-selectin) in the microvessels,115–117 ICAM-1,118–122
and P-selectin118 after focal cerebral ischemia in rodents and
in nonhuman primates.
The possible relevance of adhesion molecules to the
pathogenesis of ischemic brain damage has recently been
corroborated by two studies demonstrating that, in compari-
son with normal controls, mice belonging to an ICAM-1–
deficient strain show a marked reduction in cerebral infarc-
tion size after transient MCA occlusion.35,123 As reviewed by
Feuerstein et al,74 cytokines can also induce the in vitro
expression of adhesion molecules in astrocytes, oligodendro-
cytes, and microglia. It is postulated that the presence of
adhesion molecules on the surface of glial cells may facilitate
the postischemic migration of leukocytes through the brain
parenchyma.74
One observation with potential clinical relevance is that the
expression of adhesion molecules caused by administration of
IL-1, TNF-a, and IFN-g is higher in endothelial cell cultures
from spontaneously hypertensive rats than in those derived
from normotensive rats.124 This finding suggests that ischemic
injuries of comparable severity may lead to more severe
consequences in hypertensive individuals.
Upregulation of adhesion molecules has been documented
in human stroke patients. In a preliminary study, leukocytes
from patients suffering an ischemic stroke or transient ische-
mic attack showed increased CD11a expression within 72
hours of the onset of symptoms in comparison with control
subjects matched for age and risk factors.125 Sobel et al126
detected increased ICAM-1 expression on the surface of
vessels from cerebral cortical infarcts in four patients. Soluble
isoforms of adhesion molecules, which are believed to be
shed from the surfaces of activated cells, can be quantified in
serum: in comparison with normal control subjects, patients
with acute stroke showed an initial increase in serum endo-
thelial-leukocyte adhesion molecule-1 levels (up to 24 hours
after stroke) and persistently increased levels of vascular cell
adhesion molecule-1 (up to 5 days).127 This temporal pattern
is in line with the current view that selectins, such as
endothelial-leukocyte adhesion molecule-1, mediate the ini-
tial low-affinity interaction between leukocytes and endothe-
lial cells and promote the margination and rolling of leuko-
cytes in the blood stream; subsequently, it is vascular cell
adhesion molecule-1 (immunoglobulin superfamily) that
causes the tight leukocyte-endothelial attachment and
transendothelial migration.
When evaluating the levels of adhesion molecules in
patients with cerebrovascular diseases, consideration should
be given to the possible confounding effect of risk factors for
atherosclerosis, a condition involving chronic inflammatory
endothelial activation.128 In acute ischemic stroke patients,
serum ICAM-1 levels have been found to be lower than129 or
the same as127 those of asymptomatic control subjects
matched for age, sex, and a number of vascular risk factors.
It can also be hypothesized that because of the long period (up
to 72 hours) for enrolling patients, in one of these two
studies,129 the theoretical initial peak serum level of adhesion
molecules could no longer be detected after they had bound to
leukocytes and endothelial cells.
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Another group of adhesion molecules is involved in cell-
matrix interaction. Integrins, the most widely studied adhe-
sion molecules of this group, are heterodimeric membrane
glycoproteins formed by the combination of an a- and a
b-subunit with an intracellular and an extracellular domain.113
At the basal membrane level, integrins connect endothelial
cells to extracellular components, such as laminin and colla-
gen. In the brain, endothelial cells, astrocytes, and the basal
membrane contribute to form the blood-brain barrier, and
their interconnection is mediated by integrins. Damage to
these molecules may therefore lead to severe damage of the
blood-brain barrier. Wagner et al130 have demonstrated that
integrin a6b4, that under physiological conditions mediates
the interaction between astrocytes and extracellular matrix, is
rapidly damaged during focal cerebral ischemia/reperfusion.
Other integrins play an important role in inflammatory
neoangiogenesis, wound repair, and ontogenesis and may
therefore be important for tissue repair after an ischemic
insult. Among these, integrin avb3, a receptor for molecules
sharing the common arginine-glycine–aspartic acid (RGD)
sequence (eg, vitronectin, fibrinogen, fibronectin, and lami-
nin), is expressed in basal ganglia microvessels in a nonhu-
man primate model of ischemia/reperfusion as early as 2
hours after MCA occlusion.131 The binding of ligand to
integrins modifies the conformation of their intracellular
domain so as to interfere with the cytoskeleton alignment,
modify cellular structure, and confer on the cell the ability to
migrate. Through these mechanisms, avb3 might play a role
during the first stages of vascular reorganization after cere-
bral ischemia.
Chemokines in Cerebral Ischemia
As IL-1b and TNF-a play a major role in promoting adhesion
between endothelial cells and leukocytes, they are poor
attractants for polymorphonuclear leukocytes and monocytes;
other chemoattractant cytokines (the so-called chemokines)
are believed to be specifically involved in guiding leukocytes
through the parenchyma and toward the ischemic area.
Chemokines are low-molecular-weight molecules charac-
terized by the presence, as a common structural pattern, of
four cysteine residues and are divided into two main families
(C-X-C and C-C chemokines) according to the presence or
absence of an amino acid between the residues of the two
most amino-proximal cysteines.36 This structural distinction
is reflected in vitro by a peculiar effect on different cell types:
C-X-C chemokines tend to attract neutrophils, whereas C-C
chemokines preferentially act on monocytes/macrophages.
Each chemokine family binds to specific receptors formed by
seven transmembrane domains that activate G proteins and
subsequently an intracellular kinase cascade.132 Chemokine
production and secretion are stimulated by a number of
compounds, such as bacterial lipopolysaccharide, IL-1a and
-1b, and TNF-a.36
Few chemokines have so far been studied in some detail in
experimental cerebral ischemia. Significant expression of
CINC mRNA has been detected in the ischemic areas of
spontaneously hypertensive rats 6 hours after permanent
MCA occlusion133; this expression peaks at 12 hours and
rapidly decreases at 24 hours. CINC has been shown to be
homologous to three “gro” human proteins and “KC” in the
mouse, and all of them are molecules acting predominantly as
neutrophil chemoattractants.134 In a model of rat transient
focal ischemia, the first detectable level of CINC in the brain
was observed 3 hours after reperfusion and preceded leuko-
cyte infiltration.135 In the sera of the same animals, a high
concentration of CINC was found 60 minutes after MCA
occlusion, with the peak concentration being reached 3 hours
after reperfusion; a reduction in levels was observed between
6 and 48 hours.135
The temporal expression of MCP-1 in brain ischemia follows
that of CINC. High levels of MCP-1 mRNA have been found in
the brains of rats with transient and permanent MCA occlusion
at 6 hours, with the highest expression occurring between 12
hours and 2 days136,137; increased MCP-1 expression was still
detectable 5 days after permanent MCA occlusion.136 The
observations that in vitro IL-1b and TNF-a induce MCP-1 gene
expression138 and that in vivo MCP-1 mRNA temporal expres-
sion follows that of IL-1b and TNF-a mRNA45,67 suggest that
IL-1b and TNF-a induce MCP-1 expression in cerebral ische-
mia. According to Gourmala et al,139 6 hours to 2 days after
MCA occlusion, MCP-1 mRNA is present in rat astrocytes
surrounding the ischemic tissue. After 4 days, MCP-1 mRNA is
found in macrophages and microglial cells in the infarcted tissue.
The mRNA of another member of the C-C chemokine
family, MIP-1a, has been found to be overexpressed in
cerebral ischemic areas.137 This chemokine attracts mono-
cytes and macrophages and modulates their activity in tissue
undergoing an inflammatory process. Kim et al137 found that
the temporal expression of MIP-1a parallels that of MCP-1
and that the distribution of MIP-1a–positive cells was similar
to that of activated astrocytes. MIP-1a infused into the
subarachnoid space of rabbits treated with Gram-negative
bacteria initially attracts neutrophils and subsequently mono-
cytes.140 If this sequence also holds true in cerebral ischemia,
this molecule could be in part responsible for the switch from
a leukocyte- to a macrophage-based inflammatory response.
The temporal profile of CINC, MCP-1, and MIP-1a expres-
sion is in line with that of leukocyte accumulation in the
ischemic brain parenchyma of nonhuman primates. In these
models, polymorphonuclear cells are detected 24 to 72 hours
after the onset of ischemia, followed at 7 to 16 days by
monocyte and macrophage infiltration.9,13
In vitro, smooth muscle cells stimulated by IFN and IL-1b
or TNF-a produce IFN-inducible protein-10, which is a
chemoattractant for macrophages and activated T lympho-
cytes.141 Inducible protein-10 mRNA expression has been
demonstrated in the rat after endothelial damage by balloon
angioplasty.141 Because endothelial damage occurs during
brain ischemia, it seems possible that this molecule could also
play a role in this latter pathological condition.
The number of discovered chemokines is continuously
growing, and so far, more than 20 members of this cytokine
family have been identified. It is likely that in the future, the
activity of other chemokines may be found to be increased
after cerebral ischemia and their function elucidated.
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On the basis of the progress made in our understanding of
inflammatory-like mechanisms in cerebral ischemia, an in-
creasing number of molecules are currently being investi-
gated in animals for their possible effectiveness in human
acute stroke.
One group of studies has focused on therapeutic strategies
related to the role of proinflammatory cytokines. The intra-
ventricular and systemic administration of IL-1 receptor
antagonist into rats reduces the volume of infarction caused
by MCA occlusion54,59,62,64 or the ligation of one carotid artery
associated with hypoxia.61 This reduction in infarct size is
accompanied by a decreased number of leukocytes in the
ischemic hemisphere and improved neurological function.62
Similar results have been achieved by means of the topical
application of anti–IL-1b neutralizing antibody,53 zinc proto-
porphyrin,53,60,63 and fragments of lipocortin-1,58 all of which
act as IL-1 inhibitors. TGF-b administration has led to less
severe histological damage in a rabbit model of embolic
stroke100 as well as in rats subjected to permanent MCA
occlusion,101 transient global ischemia,104 and hypoxia-ische-
mia cerebral insult.103
A second group of studies has concentrated on molecules
that are capable of blocking the adhesion between endothelial
cells and leukocytes. The administration of anti–CD11b/
CD18 monoclonal antibodies at various times after reperfu-
sion reduces infarct volume in rats with MCA occlusion142,143
in a dose-dependent manner,144 although single administration
of the same drug 1 hour after permanent MCA occlusion led
to less striking effects.145 Treatment with antibodies against
ICAM-1 or integrin CD11b/CD18 is also capable of reducing
the number of apoptotic cells in the ischemic brain area.146
The use of anti–ICAM-1 antibodies reduces infarct volume
and the number of tissue polymorphonuclear leukocytes in
rats with transient MCA occlusion,147,148 but the treatment is
ineffective when administered to animals with permanent
occlusion.149 The same dichotomy between transient and
permanent ischemia has been shown in one model of spinal
cord ischemia.150 These observations suggest that drugs
blocking leukocyte-endothelial adhesion are effective only in
the presence of reperfusion.
Because monoclonal antibodies are immunogenic and
might have collateral effects in stroke patients, new nonim-
munogenic molecules are now being tested in animal models
with encouraging results.151,152 These are peptides or glyco-
proteins, which are produced by bacteria and which structur-
ally or functionally mimic cell adhesion molecules and inhibit
leukocyte function.
Conclusions
Leukocytes and Inflammatory Mediators in
Cerebral Ischemia
The studies reviewed in this article emphasize the possible
role of cytokines and cell adhesion molecules in the devel-
opment of cerebral damage caused by an ischemic insult.
Early overexpression of these inflammatory mediators pro-
motes the recruitment of leukocytes in the ischemic area and
represents a key mechanism for the evolution of tissue
damage. Leukocytes are in fact believed to have a deleterious
effect in brain ischemia. In the microvessels, they first adhere
to endothelial cells, interfering with local cerebral blood flow
and enhancing the ischemic insult. Subsequently, leukocytes
proceed through the endothelial lining and accumulate in the
ischemic area, where they release a number of toxic mole-
cules that contribute to the development of an infarction.
Relevance of Animal Models
Most of the evidence comes from animal studies; only
preliminary observations relating to humans are available. It
is plausible that our knowledge of the role of inflammation in
human stroke will considerably expand in the future, in terms
of both new molecules and a more precise definition of their
action, but it is likely that animal models will continue to
represent a fundamental source of information. The possibil-
ity that leukocyte alterations in experimental models may be
determined by the surgical procedures used to induce the
ischemic insult or by anesthesia has been refuted in a
nonhuman primate model.153 Moreover, the use of sham-
operated animals (ie, animals in which all of the phases of the
surgical procedure except artery occlusion are reproduced)
makes it possible to control for the influence of surgery and
anesthesia. Some of the substantial advantages of experimen-
tal models are the following: (1) The possibility of knowing
the exact time of onset of ischemia means that the temporal
pattern of the expression of the molecules under study can be
investigated; (2) Access to brain tissue for pathological
observation is simple; (3) New drugs can be tested. Never-
theless, it should be borne in mind that most of the conclu-
sions are based on rodent experiments because data from
nonhuman primate models (which are probably of greater
relevance to human disease) are still scarce.
Therapeutic Perspectives
Acute stroke therapy is probably destined to change over the
next few years. One of the crucial turning points will be
definition of the time interval during which the administration
of drugs is likely to be efficacious (therapeutic window),
which is not easy because of individual patient variability.
Most of the trials carried out so far suggest a very narrow (3
hours) therapeutic window, which in the case of thrombolytic
agents, is due more to the increased occurrence of hemor-
rhagic transformation than a lack of efficacy beyond this
limit. Animal and human studies have shown that the evolu-
tion of a brain infarct progresses over a longer period of
time,23,24,154,155 and so the reopening of an artery could also be
advantageous at a later time.
New drugs counteracting cytokine-mediated damage or
opposing leukocyte–endothelial cell adhesion are already
being investigated in animals with encouraging results. One
perspective for the use of drugs capable of interfering with
inflammation-related mechanisms is the possibility of widen-
ing the therapeutic window; in a rabbit model of embolic
stroke, administration of anti–ICAM-1 antibodies has been
shown to extend the time during which the thrombolytic
agent was effective in dissolving blood clots.156 The timing of
arrival of many stroke patients to the emergency depart-
ment157 seems compatible with potential drug interventions
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designed to interfere with inflammatory mediators and the
natural evolution of the ischemic lesion. The inflammatory
response of the cerebral parenchyma, with the above-dis-
cussed harmful implications, develops over days after the
onset of ischemia in the animal,20 and this is probably also
true in humans.12 Therefore, these therapeutic strategies could
theoretically be undertaken far beyond the strict time limit of
thrombolysis with some beneficial effects.
Possible future pharmacological treatments could be based
on the inhibition of proinflammatory mediators (perhaps IL-1
and TNF-a) or enhancement of the effect of others (IL-6 and
TGF-b). Some cytokines and chemokines, such as IFN-g and
MIP-1, seem to play a role in the passage from the first phase
of the inflammatory response, characterized by the presence
of polymorphonuclear cells, to the second, with monocyte
and macrophage invasion and the development of frank
necrosis. Blocking these molecules could prevent part of the
brain parenchyma from becoming necrotic. Interfering with
adhesion between leukocytes and endothelial cells represents
a second therapeutic option. On the other hand, attempts
could be made to potentiate the role of integrins that promote
cell remodeling and neovascularization. Other targets for a
possible pharmacological approach are the specific transduc-
tion pathway signals (eg, intracytoplasmic kinases) that are
critical for cytokine production and their effects.
Caveats and Limitations
An understanding of the role of leukocytes and the mediators
of inflammation in cerebral ischemia may have a very great
impact on therapy, but a few notes of caution should be
outlined. Although it currently seems that some cytokines,
such as IL-1, have a detrimental effect and that others, such
as TGF-b and IL-6, might be protective in some way, the
precise effect of each mediator is still not completely known.
Moreover, some data exist challenging the view that leuko-
cytes are active in favoring the progression from cerebral
ischemia to necrosis.158–160
The expectations aroused by animal studies have been
somewhat dampened by the results of the first human trial
using an anti–ICAM-1 murine monoclonal antibody (Enli-
momab, Boehringer Ingelheim). In this double-blind, place-
bo-controlled trial, 625 patients with acute ischemic stroke
were randomized within the first 6 hours of symptom onset to
receive either anti–ICAM-1 antibodies (160 mg IV the first
day, followed by 40 mg/d for 2 to 5 days after onset) or
placebo.161 The 90-day outcome as measured by the modified
Rankin Scale showed an improvement in 33% of the patients
on placebo versus 27% of those receiving active treatment.
Side effects (mainly fever, infections, and pneumonia) were
recorded in 44% of the Enlimomab and 30% of the placebo
patients; serious adverse effects (stroke progression, brain
edema, and hemorrhagic transformation of the infarction)
were observed in 22% of the Enlimomab versus 16% of the
placebo patients; both of these differences were statistically
significant. Moreover, the occurrence of cases of aseptic
meningitis in the Enlimomab group underlines the limitations
due to the immunogenic effect of this drug.
Is There Still a Role for Anti-Leukocytes
Interventions in Human Stroke?
However, before setting aside anti–ICAM-1 antibodies as
another ineffective drug in acute ischemic stroke, the prelim-
inary results of the Enlimomab study should be critically
considered. First of all, anti-leukocyte interventions appear to
be particularly effective against reperfusion injury. Anti–
ICAM-1 antibodies have been tested and proved efficacious
in models of transient146–148,150 but not permanent149 focal
ischemia, presumably the condition of most of the patients
enrolled in the Enlimomab trial. As shown by Bowes et al,156
the use of anti–ICAM-1 might be beneficial only in combi-
nation with thrombolysis. Second, the time and route of drug
administration could be crucial: in none of the reviewed
animal studies was the first dose of anti–ICAM-1 antibodies
delayed beyond 1 hour after reperfusion, and systemic ad-
ministration could lead to a reduction in host defenses and a
predisposition to infections. Finally, given the increased
frequency of fever and aseptic meningitis among the treated
patients, the immunogenic role of anti–ICAM-1 antibodies
needs to be weighed very carefully.
In the light of the above considerations, among others, a
multitherapeutic approach for ischemic stroke can be fore-
seen.162 The testing of new anti-leukocyte drugs in humans
probably requires further elucidation of the pathophysiolog-
ical role that these cells play during cerebral ischemia. At
present, it would be dangerous to simply dismiss those drugs
that may prove to be efficacious in different target
populations.
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